Related Experiment Video

Updated: Jul 7, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Primary prevention of cardiovascular disease in people with dysglycemia

Cristina Bianchi1, Roberto Miccoli, Giuseppe Penno

  • 1Department of Endocrinology and Metabolism, University of Pisa, Pisa, Italy.

Diabetes Care
|February 15, 2008
PubMed

Insights

Type 2 diabetes significantly increases cardiovascular disease risk. Early intervention and blood glucose management are crucial for reducing heart attack and mortality rates in diabetic patients.

Area of Science:

  • Endocrinology
  • Cardiology
  • Public Health

Background:

  • Cardiovascular disease (CVD) is the leading cause of death in type 2 diabetes patients.
  • Diabetic patients have a 26-36% prevalence of CVD, with higher fatality rates post-myocardial infarction and worse coronary heart disease prognosis.
  • Impaired glucose tolerance and elevated blood glucose are linked to increased cardiovascular risk and mortality.

Purpose of the Study:

  • To evaluate the role of dysglycemia as a cardiovascular disease risk equivalent.
  • To determine if diabetes should be considered a coronary heart disease risk equivalent, necessitating early intervention.
  • To explore the impact of managing blood glucose levels on cardiovascular outcomes.

Main Methods:

  • Review of epidemiological data and World Health Organization prevalence statistics.
  • Analysis of experimental studies on glucose levels and atherosclerosis mechanisms.
  • Examination of findings from diabetes prevention trials, including the STOP-NIDDM trial.

Main Results:

  • Diabetes is proposed as a coronary heart disease risk equivalent due to increased CVD prevalence and mortality.
  • Experimental data suggests elevated glucose triggers atherosclerosis pathways.
  • Diabetes prevention trials show improved cardiovascular risk factors and reduced CVD events with glucose management.

Conclusions:

  • Dysglycemia, including impaired glucose tolerance and elevated blood glucose, should be recognized as a significant cardiovascular risk factor.
  • Early detection and treatment of dysglycemia are essential for improving cardiovascular morbidity and mortality in diabetic and pre-diabetic individuals.
  • Targeting postprandial glucose, as seen in the STOP-NIDDM trial, can reduce hypertension and cardiovascular events.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...